Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt
Open Access
- 1 April 2016
- journal article
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 2 (2) , e55
Abstract
Objective: To describe the long-term follow-up and distinct phenotype of a large cohort of patients with Gaucher disease type 3 on enzyme replacement therapy (ERT) in Egypt. Methods: A prospective cohort study of 78 patients on ERT who were followed for up to 9 years with yearly evaluations that included EEG and cognitive testing. Results: Of the patients, 73% were homozygous for the L444P GBA1 mutation; all but 7 were neurologically symptomatic. Supranuclear gaze palsy with variable but stable cognitive function was present in 91% of patients. Convergent strabismus and bulbar dysfunction were noted in 22% and 37%, respectively. Features of oppositional defiant disorder were present in 54% of patients. Twenty-three patients (30%) developed seizures while on ERT for 1–9 years. Of those, 12 patients (15%) died suddenly and unexpectedly at a mean age of 6.7 ± 5.0 years (range 1.5–18). Sudden death was usually associated with a seizure disorder or a terminal seizure, but 7 of 12 patients had a preceding normal EEG. An additional 11% had background slowing or epileptogenic activity on EEG without clinical seizures. There were 3 familial cases of sudden unexpected death. Conclusions: Despite having the most common GBA1 genotype known to be associated with neuronopathic Gaucher disease, patients with Gaucher disease type 3 in Egypt have a phenotype and a clinical outcome on ERT that are very different from those observed in other populations. Identifying putative modifying genes of this ethnic group is likely to lead to better therapy for neuronopathic Gaucher disease generally.Keywords
This publication has 30 references indexed in Scilit:
- Sudden unexpected death in epilepsy: basic mechanisms and clinical implications for preventionJournal of Neurology, Neurosurgery & Psychiatry, 2015
- Sudden unexpected death in epilepsy: Assessing the public health burdenEpilepsia, 2014
- Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapyBlood Cells, Molecules, and Diseases, 2013
- Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trialsThe Lancet Neurology, 2011
- Clinical and genetic study of Japanese patients with type 3 Gaucher diseaseMolecular Genetics and Metabolism, 2009
- Cognitive Outcome in Treated Patients with Chronic Neuronopathic Gaucher DiseaseThe Journal of Pediatrics, 2008
- Outcome of type III Gaucher disease on enzyme replacement therapy: Review of 55 casesJournal of Inherited Metabolic Disease, 2007
- Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patientsJournal of Inherited Metabolic Disease, 2006
- Prospective study of neurological responses to treatment with macrophage‐targeted glucocerebrosidase in patients with type 3 Gaucher's diseaseAnnals of Neurology, 1997
- 55-Base pair deletion in certain patients with Gaucher disease complicates screening for common Gaucher allelesAmerican Journal of Medical Genetics, 1996